Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation
Takako Inoue(Nagoya City University Hospital), Yasuhito Tanaka(Kumamoto University), Katsumi Aoyagi(Fujirebio (Japan)), Atsushi Kaneko(Japanese Red Cross Nagoya Daiichi Hospital), Etsuko Iio(Nagoya City University), Shigeru Kusumoto, Takanori Suzuki(Nagoya City University), Shintaro Yagi(Advanced Life Science Institute), Kentaro Matsuura(Nagoya City University), Shintaro Ogawa(Nagoya City University)
Cited by 110
Related Papers
Incidence of arrhythmias and heart rate variability in wild-type rats exposed to social stress
|American Journal of Physiology-Heart and Circulatory Physiology|1997|156
Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study
|Clinical Infectious Diseases|2015|149
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels
|Journal of Hepatology|2022|121
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)
|Clinical Gastroenterology and Hepatology|2020|103